source
- Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipelineVedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…
- FDA gives modest backing to Moderna’s flu vaccine, noting efficacy questions but no major concernsThe FDA released briefing documents ahead of an advisory committee meeting on Moderna’s seasonal influenza vaccine. The agency’s assessment was described as tepid, highlighting some questions abou…